Patient Profiles in mCSPC

View hypothetical treatment scenarios

Select from the 2 tabs below to view profiles of patients with mCSPC. These are hypothetical patient scenarios and model portrayals.

Anthony Thumbnail

Not an actual patient.

ANTHONY

De Novo, Bone-Only
Metastasis

TOM

Elderly With
a Comorbidity

Clinical characteristics

  PSA:   71 ng/mL

  Gleason score at initial diagnosis:   7 (4+3)*

  Extent of disease:   5 bone metastases

Medical history

  • Anthony visited his primary care physician after experiencing mild but persistent hip pain
  • After assessing a hip X-ray, his physician recommended that he get his PSA checked
  • Test results showed a PSA of 71 ng/mL
  • Imaging revealed 5 bone lesions distributed in the pelvis and femur
  • After biopsy confirmation, Anthony was diagnosed with mCSPC
  • He has not yet started ADT

Not an actual patient.

Treatment considerations

  • Anthony is newly diagnosed with mCSPC
  • He has bony disease; there are no visceral metastases
  • He is minimally symptomatic (ECOG PS=1)

In the TITAN study:

  • ERLEADA® + ADT reduced the risk of death by 33% vs placebo + ADT (median overall survival NE vs NE; HR=0.67; 95% CI: 0.51, 0.89; P=0.0053)1
  • ERLEADA® + ADT reduced the risk of radiographic progression or death by 52% vs placebo + ADT (median rPFS NE vs 22.1 months; HR=0.48; 95% CI: 0.39, 0.60; P<0.0001)1
  • Consistent improvement in overall survival and rPFS was observed with ERLEADA® + ADT vs placebo + ADT, regardless of disease volume (high vs low) and Gleason score at diagnosis (≤7 vs >7)1

For your patients with mCSPC like ANTHONY:

Prescribe ERLEADA®

Learn more about the TITAN study design and efficacy results

View hypothetical treatment scenarios

ANTHONY

De Novo, Bone-Only
Metastasis

TOM

Elderly With a Comorbidity

*Equivalent to Grade Group 3.2

Study Design: TITAN was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of patients with mCSPC (N=1052). Patients had newly diagnosed mCSPC or relapsed metastatic disease after an initial diagnosis of localized disease. Patients with visceral (ie, liver or lung) metastases as the only sites of metastases were excluded. Patients were randomized 1:1 to receive ERLEADA® 240 mg orally once daily or placebo orally once daily. All patients in the TITAN trial received a concomitant GnRH analog or had a prior bilateral orchiectomy. The dual primary endpoints were overall survival and rPFS. Overall survival was defined as the time from randomization to the date of death from any cause. rPFS was based on investigator assessment and was defined as time from randomization to radiographic disease progression or death. Radiographic disease progression was defined by identification of 2 or more new bone lesions on a bone scan with confirmation (Prostate Cancer Working Group 2 criteria) and/or progression in soft tissue disease.1,3

High volume of disease was defined as metastases involving the viscera with 1 bone lesion or the presence of 4 or more bone lesions, at least 1 of which must be in a bony structure beyond the vertebral column and pelvic bones.1

Learn more about the TITAN study design

ADT = androgen deprivation therapy; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group Performance Status; GnRH = gonadotropin-releasing hormone; HR = hazard ratio; mCSPC = metastatic castration-sensitive prostate cancer; NE = not estimable; PSA = prostate-specific antigen; rPFS = radiographic progression-free survival; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.

References:

ANTHONY

De Novo, Bone-Only
Metastasis

Tom Thumbnail

Not an actual patient.

TOM

Elderly With a
Comorbidity

Clinical characteristics

  PSA :   14 ng/mL

  Gleason score at initial diagnosis:   7 (3+4)

  Extent of disease:   3 bone metastases and 1 lymph node metastasis

Medical history

  • Tom was initially diagnosed with localized prostate cancer and received external-beam radiation therapy
  • 7 years after his definitive local therapy, his PSA started to rise
  • After discussing potential treatment options with his physician, Tom refused salvage therapy and chose observation
  • His PSA is currently 14 ng/mL
  • Recent imaging tests detected 3 pelvic bone lesions and 1 pelvic lymph node metastasis; Tom was diagnosed with mCSPC
  • He started ADT with a GnRH analog 2 weeks ago
  • He has mild hepatic impairment (Child-Pugh Class A)

Not an actual patient.

Treatment considerations

  • Tom is elderly
  • He has mild hepatic impairment

In the TITAN study:

  • ERLEADA® + ADT reduced the risk of death by 33% vs placebo + ADT (median overall survival NE vs NE; HR=0.67; 95% CI: 0.51, 0.89; P=0.0053)1
  • ERLEADA® + ADT reduced the risk of radiographic progression or death by 52% vs placebo + ADT (median rPFS NE vs 22.1 months; HR=0.48; 95% CI: 0.39, 0.60; P<0.0001)1
  • Consistent improvement in overall survival and rPFS was observed with ERLEADA® + ADT vs placebo + ADT, regardless of disease volume (high vs low) and Gleason score at diagnosis (≤7 vs >7)1

For your patients with mCSPC like TOM:

Prescribe ERLEADA®

Learn more about the TITAN study design and efficacy results

View hypothetical treatment scenarios

ANTHONY

De Novo, Bone-Only
Metastasis

TOM

Elderly With a Comorbidity

*Equivalent to Grade Group 2.2

Study Design: TITAN was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of patients with mCSPC (N=1052). Patients had newly diagnosed mCSPC or relapsed metastatic disease after an initial diagnosis of localized disease. Patients with visceral (ie, liver or lung) metastases as the only sites of metastases were excluded. Patients were randomized 1:1 to receive ERLEADA® 240 mg orally once daily or placebo orally once daily. All patients in the TITAN trial received a concomitant GnRH analog or had a prior bilateral orchiectomy. The dual primary endpoints were overall survival and rPFS. Overall survival was defined as the time from randomization to the date of death from any cause. rPFS was based on investigator assessment and was defined as time from randomization to radiographic disease progression or death. Radiographic disease progression was defined by identification of 2 or more new bone lesions on a bone scan with confirmation (Prostate Cancer Working Group 2 criteria) and/or progression in soft tissue disease.1,3

High volume of disease was defined as metastases involving the viscera with 1 bone lesion or the presence of 4 or more bone lesions, at least 1 of which must be in a bony structure beyond the vertebral column and pelvic bones.1

Learn more about the TITAN study design

ADT = androgen deprivation therapy; CI = confidence interval; GnRH = gonadotropin-releasing hormone; HR = hazard ratio; mCSPC = metastatic castration-sensitive prostate cancer; NE = not estimable; PSA = prostate-specific antigen; rPFS = radiographic progression-free survival; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.

References: